Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Breast 1

Conditions

Prostatic Neoplasms 1Ovarian Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 27Docetaxel 20Cyclophosphamide 18Surveys and Questionnaires 15Therapeutics 14Radiotherapy 13Paclitaxel 12Psychiatric Rehabilitation 11Early Intervention, Educational 11Carboplatin 11Standard of Care 10olaparib 9Zoledronic Acid 9Specimen Handling 9Radiosurgery 9Magnetic Resonance Spectroscopy 9Interviews as Topic 9Gemcitabine 9Trastuzumab 8Methods 8Fulvestrant 8palbociclib 7fludarabine 7durvalumab 7Taxes 7Nivolumab 7Fluorodeoxyglucose F18 7Flow Cytometry 7Educational Status 7Blood Specimen Collection 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × CYH33 × Genitourinary × Clear all
NCT04586335 2024-03-21

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

Haihe Biopharma Co., Ltd.

Phase 1 Terminated
24 enrolled
BreastGenitourinaryGynecologic

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡